Sarah Bos

34 CHAPTER 2 16. Stine JG, Niccum BA, Zimmet AN, et al. Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis. Clin Transl Gastroenterol. 2018;9(3):140. 17. Stine JG, Argo CK, Pelletier SJ, Maluf DG, Caldwell SH, Northup PG. Advanced non- alcoholic steatohepatitis cirrhosis: A high-risk population for pre-liver transplant portal vein thrombosis. World J Hepatol. 2017;9(3):139-146. 18. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15. 19. Lisman T, Groot PG De, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood. 2005;105(3):1102-1105. 20. Ariëns R a, Philippou H, Nagaswami C, Weisel JW, Lane D a, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood. 2000;96(3):988-995. 21. LimBCB, Ariëns RAS, Carter AM, Weisel JW, Grant PJ. Genetic regulation of fibrin structure and function: Complex gene-environment interactions may modulate vascular risk. Lancet. 2003;361(9367):1424-1431. 22. Groeneveld DJ, Adelmeijer J, Hugenholtz GCG, Ariëns RAS, Porte RJ, Lisman T. Ex vivo addition of fibrinogen concentrate improves the fibrin network structure in plasma samples taken during liver transplantation. J Thromb Haemost. 2015;13(12):2192-2201. 23. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005;129(1):93-100. 24. Eckmann CM, de Laaf RTM, van Keulen JM, van Mourik JA, de Laat B. Bilirubin oxidase as a solution for the interference of hyperbilirubinemia with ADAMTS-13 activity measurement by FRETS-VWF73 assay. J Thromb Haemost. 2007;5(6):1330-1331. 25. Kuboki S, Shimizu H, Ohtsuka M, et al. Incidence, risk factors, and management options for portal vein thrombosis after hepatectomy: a 14-year, single-center experience. Am J Surg. 2015;210(5):878-885.e2. 26. Emuakhagbon V, Philips P, Agopian V, Kaldas FM, Jones CM. Incidence and risk factors for deep venous thrombosis and pulmonary embolus after liver transplantation. Am J Surg. 2016;211(4):768-771. 27. Zhou W, Inada M, Lee T-P, et al. ADAMTS13 is expressed in hepatic stellate cells. Lab Invest. 2005;85(6):780-788. 28. Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005;106(3):922-924. 29. Russo FP, Zanetto A, Campello E, et al. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int. 2018:1-9. 30. Sinegre T, Duron C, Lecompte T, et al. Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis. J Thromb Haemost. 2018;16:1-9. 31. LebretonA, SinegreT, PereiraB, LamblinG, DuronC, Abergel A. Plasmahypercoagulability in the presence of thrombomodulin but not of activated protein C in patients with cirrhosis. J Gastroenterol Hepatol. 2017;32(4):916-924. 32. Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis - Possibilities and caveats. J Hepatol. 2013;59(2):358-366.